Molecular mousetraps, α1-antitrypsin deficiency and the serpinopathies

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 5, Issue 3, 2005, Pages 249-257

  Lomas, David A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Conformational disease; Neuroserpin; Polymerisation; Serpins; 1 antitrypsin

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ANTITHROMBIN; COMPLEMENT COMPONENT C1S INHIBITOR; MUTANT PROTEIN; POLYMER; SERINE PROTEINASE INHIBITOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANGIONEUROTIC EDEMA; ANIMAL CELL; CONFERENCE PAPER; DEMENTIA; DISEASE SEVERITY; EMPHYSEMA; FAMILIAL ENCEPHALOPATHY WITH NEUROSERPIN INCLUSION BODY; GENETIC STABILITY; HUMAN; LIVER CELL; LIVER CIRRHOSIS; NONHUMAN; PERIODIC ACID SCHIFF STAIN; POINT MUTATION; PROTEIN FAMILY; PROTEIN POLYMERIZATION; PROTEIN SECRETION; THROMBOSIS; CELL INCLUSION; CHEMISTRY; GENETICS; METABOLISM; REVIEW;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; HUMANS; INCLUSION BODIES; POINT MUTATION;

EID: 21744457450     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.5-3-249     Document Type: Conference Paper

References (96)

1. Silverman GA, Bird PI, Carrell RW, Church FC et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, novel functions, mechanism of inhibition and a revised nomenclature. J Biol Chem 2001;276:33293-6.
2. 1-antitrypsin. Nat Struct Biol 1996;3: 676-81.
3. 1-antitrypsin at 2.7 Å. Structure 1996;4:1181-92.
4. 1- antitrypsin is in the canonical inhibitory conformation. J Mol Biol 1998;275:419-25.
5. 1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Science 2000;9:1274-81.
6. 1-antitrypsin shows variability of the reactive centre and other loops. J Mol Biol 2001;306:109-19.
7. Jin L, Abrahams J-P, Skinner R, Petitou M et al. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997;94: 14683-8.
8. Li J, Wang Z, Canagarajah B, Jiang H et al. The structure of active serpin 1K from Manduca sexta. Structure 1999;7:103-9.
9. Wilczynska M, Fa M, Ohlsson P-I, Ny T. The inhibition mechanism of serpins. Evidence that the mobile reactive centre loop is cleaved in the native protease-inhibitor complex. J Biol Chem 1995;270:29652-5.
10. Wilczynska M, Fa M, Karolin J, Ohlsson P-I et al. Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat Struc Biol 1997;4:354-7.
11. Stratikos E, Gettins PGW. Major proteinase movement upon stable serpin-proteinase complex formation. Proc Natl Acad Sci 1997;4:453-8.
12. 1-antitrypsin inhibitor Pittsburgh. J Biol Chem 1998;273:15582-9.
13. Stratikos E, Gettins PGW. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive centre loop into β-sheet A. Proc Natl Acad Sci USA 1999;96:4808-13.
14. Huntingdon JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000;407:923-6.
15. 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 1991;30:1723-30.
16. 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992;267:14543-6.
17. Andreasen PA, Sottrup-Jensen L, Kjøller L, Nykjær A et al. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett 1994;338:239-45.
18. Lomas DA, Carrell RW. Serpinopathies and the conformational dementias. Nat Rev Genet 2002;3:759-68.
19. Lomas DA, Mahadeva R. Alpha-1-antitrypsin polymerisation and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest 2002;110:1585-90.
20. 1-antitrypsin deficiency: a model for conformational diseases. N Engl J Med 2002;346:45-53.
21. Malone M, Mieli-Vergani G, Mowat AP, Portmann B. The fetal liver in PiZZ alpha-1-antitrypsin deficiency: a report of 5 cases. Pediatric Pathology 1989;9:623-31.
22. Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognised inherited disorder. J Lab Clin Med 1969;73:934-9.
23. 1-antitrypsin deficiency. N Eng J Med 1975;292:176-80.
24. 1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976;294:1316-21.
25. 1-antitrypsin deficiency in early childhood. Pediatrics 1978; 62:22-25.
26. 1- antitrypsin deficient children. Acta Paed Scand 1988;77:847-51.
27. 1- antitrypsin deficiency. Hepatology 1995;22:514-17.
28. 1-antitrypsin deficiency. N Engl J Med 1986;314:736-9.
29. 1-antitrypsin accumulation in the liver. Nature 1992;357:605-7.
30. 1-antitrypsin by a monoclonal antibody. J Biol Chem 2002; 277:26540-6.
31. 1-antitrypsin. J Biol Chem 1999; 274:9548-55.
32. 1-antitrypsin polymers are formed by reactive loop-β-sheet A linkage. J Biol Chem 2000;275:33663-8.
33. 1-antitrypsin polymerization probed by fluorescence spectroscopy. Arch Biochem Biophys 1998; 356:296-300.
34. 1- antitrypsin polymerisation: A fluorescence correlation spectroscopic study. Biochemistry 2004;In press.
35. 1-antitrypsin is preferentially selected for degradation. Proc Natl Acad Sci USA 2003;100:8229-34.
36. 1-antitrypsin. Hepatology 2004;40:1203-10.
37. 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem 1991;266:12627-32.
38. 1- antitrysin deficiency in Japan. Am Rev Respir Dis 1995;152:2119-26.
39. Roberts EA, Cox DW, Medline A, Wanless IR. Occurrence of alpha-1-antitrypsin deficiency in 155 patients with alcoholic liver disease. Am J Clin Pathol 1984;82:424-7.
40. 1-antitrypsin deficiency variant, Mnichinan. Am J Hum Genet 1990;46:602-12.
41. Sergi C, Consalez GC, Fabbretti G, Brisigotti M et al. Immunohistochemical and genetic characterization of the M Cagliari α-1-antitrypsin molecule (M-like α-1-antitrypsin deficiency). Lab Invest 1994;70:130-3.
42. Zhou A, Stein PE, Huntington JA, Carrell RW. Serpin polymerisation is prevented by a hydrogen bond network that is centered on His-334 and stabilized by glycereol. J Biol Chem 2003;278:15116-122.
43. 1-antitrypsin. J Biol Chem 1997;272: 510-16.
44. 53→Phe); further evidence for intracellular loop-sheet polymerisation. J Biol Chem 1993;268:15333-5.
45. 52Phe deleted) forms loop-sheet polymers in vivo: evidence for the C sheet mechanism of polymerisation. J Biol Chem 1995; 270:16864-70.
46. 1-antitrypsin. Nat Struct Biol 1996;3:910-11.
47. 1-antitrypsin and liver cirrhosis. J Clin Invest 1999;103:999-1006.
48. 1-antitrypsin deficiency in a 4 year old girl. Helv Paediatr Acta 1975;30:501-7.
49. Campra JL, Craig JR, Peters RL, Reynolds TB. Cirrhosis associated with partial deficiency of alpha-1-antitrypsin in an adult. Ann Intern Med 1973;78:233-8.
50. 1-antitrypsin deficiency. Scand J Clin Lab Invest 1963;15: 132-40.
51. 1-antitrypsin deficiency. Acta Med Scand 1965; suppl.432:1-85.
52. Stein PD, Leu JD, Welsh MH, Guenter CA. Pathophysiology of the pulmonary circulation in emphysema associated with alpha-1 antitrypsin deficiency. Circulation 1971;43:227-39.
53. 1-antitrypsin deficiency. Thorax 1998; 53:265-8.
54. 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987;316:1055-62.
55. 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987;80:1366-74.
56. Guzdek A, Potempa J, Dubin A, Travis J. Comparative properties of human α-1-proteinase inhibitor glycosylation variants. FEBS Lett 1990;272:125-7.
57. Lomas DA, Evans DL, Stone SR, Chang W-SW, Carrell RW. Effect of the Z mutation on the physical and inhibitory properties of α1-antitrypsin. Biochemistry 1993;32:500-8.
58. 1-antitrypsin to prevent neutrophil mediated tissue damage. Biochim Biophys Acta 1994;1227:155-60.
59. 1-antitrypsin deficiency, PiZ. Acta Med Scand 1978;204:345-51.
60. 1-antitrypsin deficiency. Lancet 1985;i:152-4.
61. 1- antitrypsin related emphysema. Am J Respir Cell Mol Biol 1998;18:670-74.
62. 1-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 2002;26:723-30.
63. 1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant Chest 2004;125:1952-7.
64. 1-antitrypsin on neutrophil activation, in vitro. Biochem Biophys Res Commun 2004;315:288-96.
65. 1-antitrypsin co-localise with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005;166:377-86.
66. 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clinical Science 1987;72:373-81.
67. 1-antitrypsin deficiency. Chest 2000:2505-2515.
68. 1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattractant. J Exp Med 1988;167:1608-15.
69. Senior RM, Griffin GL, Mecham RP. Chemotactic activity of elastin derived peptides. J Clin Invest 1980;66:859-62.
70. Golpon HA, Coldren CD, Zamora MR, Cosgrove G et al. Emphysema lung tissue gene expression profiling. Am J Respir Cell Mol Biol 2004; 31:595-600.
71. 436→Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J Biol Chem 1993;268:18088-94.
72. Eldering E, Verpy E, Roem D, Meo T, Tosi M. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J Biol Chem 1995;270:2579-87.
73. Bruce D, Perry DJ, Borg J-Y, Carrell RW, Wardell MR. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen VI (187 Asn→Asp). J Clin Invest 1994;94:2265-74.
74. Picard V, Dautzenberg M-D, Villoutreix BO, Orliaguet G et al. Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerisation in vivo associated with severe childhood thrombosis. Blood 2003;102:919-25.
75. 1-antichymotrypsin deficiency in a heterozygote with liver and lung disease. J Hepatology 1993;18:313-21.
76. 1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics 1993;17:740-3.
77. 1-antichymotrypsin indicates two stage insertion of the reactive loop; implications for inhibitory function and conformational disease. Proc Natl Acad Sci USA 2000;97:67-72.
78. Corral J, Aznar J, Gonzalez-Conejero R, del Key ML et al. Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation 2004;110:1303-7.
79. Green C, Brown G, Dafforn TR, Morley T et al. Mutations in the Drosophila serpin: Necrotic mirror disease-associated mutations of human serpins. Development 2003;130:1473-8.
80. Davis RL, Holohan PD, Shrimpton AE, Tatum AH et al. Familial encephalopathy with neuroserpin inclusion bodies (FENIB). Am J Pathol 1999;155:1901-13.
81. Davis RL, Shrimpton AE, Holohan PD, Bradshaw C et al. Familial dementia caused by polymerisation of mutant neuroserpin. Nature 1999;401:376-9.
82. Bradshaw CB, Davis RL, Shrimpton AE, Holohan PD et al. Cognitive deficits associated with a recently reported familial neurodegenerative disease. Arch Neurol 2001;58:1429-34.
83. Davis RL, Shrimpton AE, Carrell RW, Lomas DA et al. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 2002;359:2242-7.
84. Belorgey D, Crowther DC, Mahadeva R, Lomas DA. Mutant neuroserpin (Ser49Pro) that causes the familial dementia FENIB is a poor proteinase inhibitor and readily forms polymers in vitro. J Biol Chem 2002;277:17367-73.
85. Belorgey D, Sharp LK, Crowther DC, Onda M et al. Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB. Eur J Biochem 2004;271:3360-7.
86. Onda M, Belorgey D, Sharp LK, Lomas DA. Latent S49P neuroserpin spontaneously forms polymers: identification of a novel pathway of polymerization and implications for the dementia FENIB. J Biol Chem 2005;280:13735-41.
87. Miranda E, Römisch K, Lomas DA. Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J Biol Chem 2004;279:28283-91.
88. 1-antitrypsin that play structural and functional roles. Prot Sci 2001;10:1446-53.
89. 1-antitrypsin to prevent conformational disease. J Biol Chem 2003;278:33060-66.
90. Skinner R, Chang W-SW, Jin L, Pei X et al. Implications for function and therapy of a 2.9 Å structure of binary-complexed antithrombin. J Mol Biol 1998;283:9-14.
91. Fitton HL, Pike RN, Carrell RW, Chang W-SW. Mechanisms of antithrombin polymerisation and heparin activation probed by insertion of synthetic reactive loop peptides. Biol Chem 1997;378:1059-63.
92. Chang W-SW, Wardell MR, Lomas DA, Carrell RW. Probing serpin reactive loop conformations by proteolytic cleavage. Biochem J 1996;314:647-53.
93. 1-antitrypsin related cirrhosis. J Biol Chem 2002;277:6771-4.
94. 1-antitrypsin related emphysema. Am J Respir Cell Mol Biol 2004;31:133-9.
95. Zhou A, Stein PE, Huntington JA, Sivasothy P et al. How small peptides block and reverse serpin polymerization. J Mol Biol 2004;342:931-41.
96. Lomas DA, Belorgey D, Mallya M, Miranda E et al. Molecular mouse-traps and the serpinopathies. Biochem Soc Trans 2005;33 (part 2);321-30.